A drug for endometriosis and breast cancer leaves the PBS - but remains for prostate cancer RUSSH
Sex hormone related disorders, characterized by complex etiology and long-term health risks, pose a significant challenge to global health. Hormone-based therapies are often accompanied by adverse effects and fail to …
LY01021 is a novel oral small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of various sex hormone-dependent disorders. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), …
With the rapid increase in prostate cancer, it has become the most common cancer among Korean men. T.. 매일경제
NHS app to fast-track prostate cancer diagnoses coastfm.co.uk
French medical technology company EDAP secures €36 million credit facility from EIB to advance prostate cancer and endometriosis non-invasive treatment The European Sting
Modern humans and archaic hominins, namely Denisovans and Neanderthals, have a long history of admixture. Some of these admixture events have allowed modern humans to adapt to new environments outside …
Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. …
Common diabetes medication shows promise against prostate cancer indica News
Symptoms of prostate cancer after Milton Jones diagnosis Yahoo News UK